Cargando…

Development of capsid- and genome-modified optimized AAVrh74 vectors for muscle gene therapy

The first generation of adeno-associated virus (AAV) vectors composed of the naturally occurring capsids and genomes, although effective in some instances, are unlikely to be optimal for gene therapy in humans. The use of the first generation of two different AAV serotype vectors (AAV9 and AAVrh74)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shoti, Jakob, Qing, Keyun, Keeler, Geoffrey D., Duan, Dongsheng, Byrne, Barry J., Srivastava, Arun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690633/ https://www.ncbi.nlm.nih.gov/pubmed/38046199 http://dx.doi.org/10.1016/j.omtm.2023.101147

Ejemplares similares

Development of an AAV DNA-based synthetic vector for the potential gene therapy of hemophilia in children
por: Shoti, Jakob, et al.
Publicado: (2022)

Evaluation of rAAVrh74 gene therapy vector seroprevalence by measurement of total binding antibodies in patients with Duchenne muscular dystrophy
por: Goedeker, Natalie L., et al.
Publicado: (2023)

An Isolated Limb Infusion Method Allows for Broad Distribution of rAAVrh74.MCK.GALGT2 to Leg Skeletal Muscles in the Rhesus Macaque
por: Xu, Rui, et al.
Publicado: (2018)

Pre Clinical Assessment of AAVrh74.MCK.GNE Viral Vector Therapeutic Potential: Robust Activity Despite Lack of Consistent Animal Model for GNE Myopathy
por: Mitrani-Rosenbaum, Stella, et al.
Publicado: (2022)

rAAVrh74.MCK.GALGT2 Demonstrates Safety and Widespread Muscle Glycosylation after Intravenous Delivery in C57BL/6J Mice
por: Zygmunt, Deborah A., et al.
Publicado: (2019)

Capsid Modifications for Targeting and Improving the Efficacy of AAV Vectors
por: Büning, Hildegard, et al.
Publicado: (2019)

Therapeutic efficacy of rscAAVrh74.miniCMV.LIPA gene therapy in a mouse model of lysosomal acid lipase deficiency
por: Lam, Patricia, et al.
Publicado: (2022)

Microglia-specific targeting by novel capsid-modified AAV6 vectors
por: Rosario, Awilda M, et al.
Publicado: (2016)

HIV Capsid Inhibitors Beyond PF74
por: McArthur, Carole, et al.
Publicado: (2019)

Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy: A Nonrandomized Controlled Trial
por: Mendell, Jerry R., et al.
Publicado: (2020)

Dose-Escalation Study of Systemically Delivered rAAVrh74.MHCK7.micro-dystrophin in the mdx Mouse Model of Duchenne Muscular Dystrophy
por: Potter, Rachael A., et al.
Publicado: (2021)

Assessment of rAAVrh.74.MHCK7.micro-dystrophin Gene Therapy Using Magnetic Resonance Imaging in Children With Duchenne Muscular Dystrophy
por: Willcocks, Rebecca J., et al.
Publicado: (2021)

Systemic delivery of AAVrh74.tMCK.hCAPN3 rescues the phenotype in a mouse model for LGMD2A/R1
por: Sahenk, Zarife, et al.
Publicado: (2021)

Short-term treatment of golden retriever muscular dystrophy (GRMD) dogs with rAAVrh74.MHCK7.GALGT2 induces muscle glycosylation and utrophin expression but has no significant effect on muscle strength
por: Martin, Paul T., et al.
Publicado: (2021)

AAV3-miRNA vectors for growth suppression of human hepatocellular carcinoma cells in vitro and human liver tumors in a murine xenograft model in vivo
por: Yin, Ling, et al.
Publicado: (2020)

A first-in-human phase I/IIa gene transfer clinical trial for Duchenne muscular dystrophy using rAAVrh74.MCK.GALGT2
por: Flanigan, Kevin M., et al.
Publicado: (2022)

Optimization of the Capsid of Recombinant Adeno-Associated Virus 2 (AAV2) Vectors: The Final Threshold?
por: Aslanidi, George V., et al.
Publicado: (2013)

Intra-CSF AAV9 and AAVrh10 Administration in Nonhuman Primates: Promising Routes and Vectors for Which Neurological Diseases?
por: Bey, Karim, et al.
Publicado: (2020)

AAVrh10 Vector Corrects Disease Pathology in MPS IIIA Mice and Achieves Widespread Distribution of SGSH in Large Animal Brains
por: Hocquemiller, Michaël, et al.
Publicado: (2019)

AAVrh10 vector corrects pathology in animal models of GM1 gangliosidosis and achieves widespread distribution in the CNS of nonhuman primates
por: Hocquemiller, Michaël, et al.
Publicado: (2022)

Role of Essential Metal Ions in AAV Vector-Mediated Transduction
por: Rambhai, Himanshu K., et al.
Publicado: (2020)

Modifying immune responses to adeno-associated virus vectors by capsid engineering
por: Bentler, Martin, et al.
Publicado: (2023)

Selective transduction of cerebellar Purkinje and granule neurons using delivery of AAV-PHP.eB and AAVrh10 vectors at axonal terminal locations
por: Surdyka, Magdalena, et al.
Publicado: (2022)

Rational design of AAVrh10-vectored ACE2 functional domain to broadly block the cell entry of SARS-CoV-2 variants
por: Li, Minchao, et al.
Publicado: (2022)

Enhanced Transduction of Human Hematopoietic Stem Cells by AAV6 Vectors: Implications in Gene Therapy and Genome Editing
por: Yang, Hua, et al.
Publicado: (2020)

Capsid-expressing DNA in AAV vectors and its elimination by use of an oversize capsid gene for vector production
por: Halbert, Christine L., et al.
Publicado: (2010)

Development of a Bispecific Antibody-Based Platform for Retargeting of Capsid Modified AAV Vectors
por: Kuklik, Juliane, et al.
Publicado: (2021)

Persistent Expression of Biologically Active Anti-HER2 Antibody by AAVrh.10-mediated Gene Transfer
por: Wang, Guoqing, et al.
Publicado: (2010)

Can early treatment of twitcher mice with high dose AAVrh10-GALC eliminate the need for BMT?
por: Rafi, Mohammad A, et al.
Publicado: (2021)

Site-Directed Mutagenesis Improves the Transduction Efficiency of Capsid Library-Derived Recombinant AAV Vectors
por: Ran, Gai, et al.
Publicado: (2020)

Synthesis, Enantiomeric Resolution and Biological Evaluation of HIV Capsid Inhibition Activity for Racemic, (S)- and (R)-PF74
por: Ruddell, Stuart, et al.
Publicado: (2021)

Metabolite Identification of HIV-1 Capsid Modulators PF74 and 11L in Human Liver Microsomes
por: Xu, Shujing, et al.
Publicado: (2022)

Intrathecal administration of IGF-I by AAVrh10 improves sensory and motor deficits in a mouse model of diabetic neuropathy
por: Homs, Judit, et al.
Publicado: (2014)

Systemic AAVrh10 provides higher transgene expression than AAV9 in the brain and the spinal cord of neonatal mice
por: Tanguy, Yannick, et al.
Publicado: (2015)

Validation of Anti-Adeno Associated Virus Serotype rh10 (AAVrh.10) Total and Neutralizing Antibody Immunogenicity Assays
por: Butala-Flores, Elizabeth, et al.
Publicado: (2023)

Tailoring the AAV2 capsid vector for bone-targeting
por: Alméciga-Díaz, Carlos J., et al.
Publicado: (2018)

Genetic and Chemical Capsid Modifications of Adenovirus Vectors to Modulate Vector–Host Interactions
por: Weklak, Denice, et al.
Publicado: (2021)

Novel PF74-like small molecules targeting the HIV-1 capsid protein: Balance of potency and metabolic stability
por: Wang, Lei, et al.
Publicado: (2021)

Rationale and strategies for the development of safe and effective optimized AAV vectors for human gene therapy
por: Srivastava, Arun
Publicado: (2023)

AAVrh.10-mediated Genetic Delivery of Bevacizumab to the Pleura to Provide Local Anti-VEGF to Suppress Growth of Metastatic Lung Tumors
por: Watanabe, Masaki, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_odtarcf92bnta5d0u7b6cdp4vg